The article offers information on the role of development of oral tyrosine kinase inhibitors (TKIs) as a molecular-targeted therapy to treat chronic myeloid leukemia (CML). It compares the efficacy of Second-generation (2G) TKIs with ponatinib in patients who failed treatment with or demonstrated intolerance.